👥 The collaboration will cover the manufacturing of the drug substance at Lonza’s facility in New Hampshire.
🧪 Sabirnetug is the first antibody to demonstrate target engagement of toxic soluble amyloid beta oligomers.
💡 The antibody addresses an underlying cause of Alzheimer’s by preventing these toxic oligomers from binding to neurons.
⏩ This collaboration will help accelerate the development of potential treatments for Alzheimer’s disease.
Introduction:
Acumen Pharmaceuticals has signed a collaboration agreement with Lonza for the manufacturing of sabirnetug (ACU193), a monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s Disease (AD). This collaboration will cover the manufacturing of the drug substance for clinical development and commercialization, if approved.
- Sabirnetug is the first humanized monoclonal antibody to selectively target AβOs in a Phase I first-in-human study, addressing a key underlying cause of AD.
- Lonza will manufacture the drug substance at its next-generation manufacturing facility in Portsmouth, NH, equipped with 2,000L single-use bioreactors.
- Acumen will leverage Lonza’s regulatory expertise, experience in antibody manufacturing, and global manufacturing network.
- The collaboration aims to advance the development of sabirnetug as a potential treatment option for early AD.
- This collaboration highlights Lonza’s flexibility and commitment to enabling innovative biotech companies in accelerating their therapies.
Conclusion:
This collaboration between Acumen Pharmaceuticals and Lonza for the manufacturing of sabirnetug is a significant step in the development of a potentially effective treatment for Alzheimer’s Disease. By targeting toxic AβOs, sabirnetug addresses an underlying cause of the disease and offers hope for patients and their families. Lonza’s manufacturing expertise and facilities will support the clinical development and potential commercialization of this promising therapy.
